Edwards Lifesciences Corp (EW)

Return on equity (ROE)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	1,402,400	1,430,900	1,389,500	1,488,800	1,521,900	1,458,800	1,455,400	1,538,500	1,503,100	2,063,200	2,048,300	1,436,900	1,409,300	1,401,800	1,351,300	1,715,500	1,654,600	1,689,700	1,640,900	1,681,300
Total stockholders’ equity	US$ in thousands	6,650,000	6,657,500	6,375,700	5,978,000	5,806,700	6,217,800	5,943,600	5,844,900	5,835,900	5,541,300	5,133,300	4,658,400	4,574,300	4,210,300	3,839,100	3,901,100	4,148,300	3,814,800	3,500,300	3,447,500
ROE		21.09%	21.49%	21.79%	24.90%	26.21%	23.46%	24.49%	26.32%	25.76%	37.23%	39.90%	30.85%	30.81%	33.29%	35.20%	43.97%	39.89%	44.29%	46.88%	48.77%

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $1,402,400K ÷ $6,650,000K
= 21.09%

Over the past eight quarters, Edwards Lifesciences Corp has demonstrated relatively stable return on equity (ROE) ranging from 21.09% to 26.32%. The company's ROE peaked at 26.32% in Q1 2022 and has since shown a slight downward trend, with a dip to 21.09% in Q4 2023. Despite these fluctuations, the ROE figures indicate that the company has been effectively utilizing its shareholders' equity to generate profits. It is important for stakeholders to monitor the ROE over time to assess the company's profitability and efficiency in generating returns for its equity holders.